Da Hee Han, PharmD

Most Recent Articles by Da Hee Han, PharmD

First-of-Its-Kind Migraine Drug Receives FDA Approval

First-of-Its-Kind Migraine Drug Receives FDA Approval

By

The efficacy of Aimovig was evaluated as a preventive treatment of episodic or chronic migraine in 3 randomized, double-blind, placebo-controlled studies: 2 studies in patients with episodic migraine (4-14 migraine days per month) and 1 study in patients with chronic migraine (≥15 headache days per month with ≥8 migraine days per month).

FDA: Possible Risk of Neural Tube Birth Defects With Certain HIV Meds

FDA: Possible Risk of Neural Tube Birth Defects With Certain HIV Meds

By

The Agency has received reports of serious neural tube birth defects involving the brain, spine, and spinal cord in babies born to women who received dolutegravir for HIV treatment.

CDC: Recommendations on the Use of Heplisav-B Published

CDC: Recommendations on the Use of Heplisav-B Published

By

Benefits of protection with 2 doses administered over 1 month make the vaccine an important option for prevention of HBV.

Fycompa sNDA Submitted for Pediatric Seizure Indications

Fycompa sNDA Submitted for Pediatric Seizure Indications

By

The proposed pediatric indications are based on a 2018 Draft Guidance that supports extrapolating efficacy data of approved drugs to treat POS in adults to pediatric patients aged ≥4 years.

Cholesterol drug may lower risk for death and cardiovascular events

Cholesterol drug may lower risk for death and cardiovascular events

By

Alirocumab significantly decreased severe cardiovascular risks in patients with acute coronary syndrome.

More Articles by Da Hee Han, PharmD

Sign Up for Free e-newsletters